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Temozolomide, an oral DNA methylator that inactivates the DNA repair enzyme O
6-alkylguanine-DNA alkyltransferase (AGAT), has
demonstrated anticancer activity on protracted schedules. Protracted schedules may lead to an ‘autoenhancement’ of
temozolomide’s inherent cytotoxic potential by cumulative reduction of the cell’s capacity for AGAT-mediated DNA repair and
resistance. This study was undertaken to characterise AGAT inactivation and regeneration in the peripheral blood mononuclear cells
(PBMCs) of patients treated on two protracted temozolomide schedules. O
6-alkyl guanine-DNA alkyltransferase activity was
measured in the PBMCs of patients treated on two phase I protracted temozolomide studies. Patients were treated daily for either 7
days every 2 weeks (Schedule A) or 21 days every 4 weeks (Schedule B). The effects of various temozolomide doses (75–
175mgm
 2), treatment duration (7–21 days), and temozolomide plasma levels on AGAT inactivation and regeneration, as well as
the relation between AGAT inactivation and toxicity, were studied. O
6-alkyl guanine-DNA alkyltransferase activity in PBMCs was
measured serially in 52 patients. Marked inactivation of AGAT occurred following 7 days of temozolomide treatment, with mean
AGAT activity decreasing by 72% (Po0.0001). Similarly, mean AGAT activity decreased by 63 and 73% after 14 and 21 days of
treatment, respectively (Po0.001 for both comparisons). O
6-alkyl guanine-DNA alkyltransferase inactivation was greater after 7 days
of treatment with higher doses of temozolomide than lower doses and remained markedly reduced 7 days post-treatment. However,
AGAT inactivation following temozolomide treatment for 14 and 21 days was similar at all doses. On the continuous 21-day
schedule, AGAT inactivation was significantly greater in patients who experienced severe thrombocytopenia than those who did not
(90.375.5 vs 72.5716.1%, Po0.045). In Conclusion, protracted administration of temozolomide, even at relatively low daily doses,
leads to significant and prolonged depletion of AGAT activity, which may enhance the antitumour activity of the agent.
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Temozolomide (Temodar, SCH52365, NSC362856), an oral
imidazotetrazinone methylating agent, undergoes spontaneous
conversion in plasma to its active methylating species, 3-methyl-
(triazen-1yl)imidazole-4-carboxamide (MTIC) (Hickman et al,
1985; Stevens et al, 1987; Tsang et al, 1990, 1991). In both
preclinical and clinical investigations, temozolomide has demon-
strated markedly schedule-dependent anticancer activity, with
more frequent treatment schedules generally producing greater
cytotoxicity than less frequent schedules (Stevens et al, 1987). In
one series of studies, temozolomide’s activity against several
human tumour xenografts was much greater when the agent was
administered daily for 5 days compared to schedules, in which an
equivalent total dose was administered every other day or as a
single treatment (Stevens et al, 1987). In sequential phase I studies
of temozolomide, the response rate was also greater with
temozolomide administered daily for 5 days every 4 weeks than
when an equivalent total dose was administered as a single
treatment every 4 weeks (7 of 42 (17%) vs 0 of 51 (0%)) (Newlands
et al, 1992).
The temozolomide dose schedule that has been granted
regulatory approval for treating patients with refractory anaplastic
astrocytoma is 150–200mgm
2day
 1 for 5 days every 4 weeks;
however, intriguing results have recently been noted with
temozolomide administered on protracted low-dose schedules. A
47% response rate was noted in patients with recurrent
glioblastoma multiforme who were treated with temozolomide,
75–100mgm
2day
 1, on a protracted daily schedule for 6–7
weeks, which compares favourably with the response rate in
similar patients treated with temozolomide on its approved dose
schedule (Newlands et al, 1992; Bower et al, 1997; Brock et al,
1998).
One mechanism that has been proposed to explain the schedule-
dependent anticancer activity of temozolomide, as well as the
encouraging, although preliminary, results noted with protracted
low-dose schedules, is that frequent temozolomide treatment,
particularly on protracted schedules, may lead to marked,
cumulative, and sustained inactivation of O
6-alkylguanine-DNA
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lalkyltransferase (AGAT). O
6-alkylguanine-DNA alkyltransferase is
an ubiquitous DNA repair enzyme that removes naturally
occurring DNA damage because of methylating and alkylating
lesions at the O
6 position of guanine and covalently links these
methyl and alkyl groups to an internal cysteine amino acid present
within the AGAT protein (Tano et al, 1990; Walter et al, 2001;
Zhou et al, 2001). As a consequence of this ‘housekeeping’
function, AGAT confers cellular resistance to chemotherapeutic
agents that principally target the O
6 position of guanine, including
chloroethylating (e.g. BCNU, and CCNU) and methylating (e.g.
procarbazine, streptozotocin, dacarbazine, and temozolomide)
agents (Dumenco et al, 1989; Schold et al, 1989; Tano et al,
1990; Jaeckle et al, 1998). In both experimental and clinical
settings, tumours with high AGAT expression have demonstrated
marked resistance to chlorethylating and methylating agents
(Dumenco et al, 1989; Schold et al, 1989; Wu et al, 1992; Friedman
et al, 1998; Jaeckle et al, 1998; Esteller et al, 2000). Following the
covalent transfer of methyl- or alkyl groups to the AGAT protein,
AGAT is irreversibly inactivated such that de novo synthesis of
new AGAT protein is required for recovery of cellular AGAT
function (Pegg, 1990; Tano et al, 1990). Therefore, administering
methylating agents, such as temozolomide, on schedules that result
in cumulative and sustained inactivation of AGAT may, in essence,
‘auto-enhance’ their own inherent cytotoxic activity by further
reducing the cell’s capacity for DNA repair and intrinsic drug
resistance (Dolan et al, 1990).
Based on the intriguing, albeit preliminary, clinical results
reported with protracted, low-dose temozolomide schedules, this
pharmacodynamic study was undertaken to characterise AGAT
inactivation and regeneration in the peripheral blood mononuclear
cells (PBMCs) of patients treated with temozolomide administered
daily for either 7 days every 2 weeks or 21 days every 4 weeks.
MATERIALS AND METHODS
Patient selection
Patients with histologic or cytologically confirmed solid malig-
nancies refractory to standard therapy, or for whom no standard
therapy existed, were entered into one of two concurrent phase I
studies of temozolomide. Patient entry criteria also included: age
X18 years; life-expectancy of at least 12 weeks; a Eastern Cooper-
ative Oncology Group (ECOG) performance status of 0–2; no
prior chemotherapy within 4 weeks (6 weeks for prior mitomycin
C or a nitrososurea); adequate haematopoietic (haemoglobin
X9gdl
 1, absolute neutrophil count (ANC) X1500ml
 1, platelet
count X100000ml
 1), hepatic (bilirubino 1.5mgdl
 1, aspartate
serum transferase (AST) and alanine serum transferase (ALT) p3
times the upper limit of normal, or o5 times the upper limit of
normal if the elevation was because of hepatic metastases), and
renal (serum creatinine p1.5mgdl
 1) functions; measurable or
evaluable disease; no prior high-dose chemotherapy requiring
haematopoietic stem cell support; and no coexisting medical
problem of sufficient severity to limit compliance with the study.
The protocol was approved by the institutional review board at
each participating centre and patients gave written informed
consent for all clinical and research aspects of the study according
to federal and institutional guidelines prior treatment.
Drug administration
Temozolomide capsules were supplied by Schering-Plough Re-
search Institute (Kenilworth, NJ, USA) in 5, 20, 100, and 250-mg
strengths. All doses were rounded up to the nearest 5-mg to
accommodate capsule strength. Patients were instructed to fast for
2h prior to dosing and 2h postdosing. Patients were also
instructed to ingest the temozolomide capsules at approximately
the same time each treatment day, and not to chew or crush the
capsules.
Treatment schedules
Patients were treated with temozolomide on one of the following
two protracted administration schedules:
Schedule A. Temozolomide administered daily for 7 days
repeated every 2 weeks. Temozolomide capsules were administered
to successive cohorts of patients at doses ranging from 50 to
175mgm
 2 orally once daily for seven consecutive days repeated
every 2 weeks. A course of therapy was defined as 4 weeks.
Schedule B. Temozolomide daily for 21 days repeated every 4
weeks. Temozolomide capsules were administered to successive
cohorts of patients at doses ranging from 50 to 150mgm
 2 orally
once daily for 21 consecutive days repeated every 4 weeks. A
course of therapy was defined as 4 weeks.
O
6-alkylguanine-DNA alkyltransferase activity
To measure AGAT activity in PBMCs, 10-ml blood samples were
collected into Vacutainer CPT
TM tubes (Becton Dickinson,
Franklin Lakes, NJ, USA) on day 1 (prior to the first dose), day
8 (24h after the seventh dose), day 15 (prior to starting second 7-
day treatment), and day 22 (24h after the last dose in course 1) in
patients receiving temozolomide on Schedule A. For patients
treated with temozolomide on Schedule B, blood sampling was
performed prior to treatment on days 1, 15, and 22 (24h after the
last dose) in course 1. Sample processing was performed within
30min of collection. The CPTt tubes were centrifuged at room
temperature for 25min at 2800 revolutions per minute (rpm)
followed by 10min at 1900rpm. The interface containing the
PBMCs was resuspended in 40ml of phosphate-buffered saline
(PBS) at 1mM EDTA, and centrifuged at 1500g for 10min at 41C.
The cells were immediately resuspended and washed again in 40ml
of PBS at 1mM EDTA. The PBS was removed and the cell pellet
frozen at  801C in an Eppendorf tube.
The activity of AGAT in PBMCs was measured by sonicating the
cells contained in the pellet and quantifying the removal of a
[
3H]methyl adduct from the O
6 position of guanine in a DNA
substrate when incubated with cell extracts as described previously
(Spiro et al, 1999).
Pharmacokinetic sampling and assay
Blood samples (5ml) for pharmacokinetic studies were collected
into prechilled syringes through an indwelling venous catheter,
emptied into prechilled heparinised tubes, and immediately cooled
in an ice water bath. Patients treated with temozolomide on
Schedule A had blood sampling performed prior to treatment on
days 1–7 and 15, as well as 15 and 30min, and 1, 1.5, 2, 2.5, 3, 4, 6,
and 8h after treatment on days 1 and 15 in course 1. For patients
treated with temozolomide on Schedule B, blood sampling was
performed prior to treatment on days 1 and 21, as well as 15 and
30min, and 1, 1.5, 2, 2.5, 3, 4, 6, and 8h after treatment on days 1
and 21 in course 1.
Within 30min of collection, the blood samples were centrifuged
at 3000rpm for 10min at 41C. Following centrifugation, 2ml of
plasma was immediately transferred to a plastic tube containing
0.10ml of 8.5% phosphoric acid. The acidified plasma was
vortexed, separated into two 1-ml aliquots, and the aliquots were
placed into plastic tubes that were frozen immediately at  201C.
A validated high-performance liquid chromatography (HPLC)
method was used to quantify plasma temozolomide concentrations
and has been described previously (Kim et al, 2001). Briefly, to
each 500ml of plasma, 500ml (50mg) of an internal standard (IS)
solution (ethazolastone, Schering Plough Research Institute,
Kenilworth, NJ, USA) and 1 N HCl (50ml) were added followed
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lby 5ml of ethyl acetate. The solution was then vortexed,
centrifuged and the organic layer transferred, and the solvent
evaporated to dryness. The residue was dissolved in 0.3ml of
mobile phase, transferred to autosampler vial inserts and 20ml was
injected onto the HPLC column. The HPLC system consisted of a
Shimdzu LC-9A pump and a Model 3200 absorbance detector
(Shimadzu Scientific Instruments, Princeton, NJ, USA) set at
316nm. Separation was accomplished on a Ultrasphere ODS, 5mm,
150 4.6mm
2 column that was preceded by an on-line filter. The
mobile phase, which consisted of 0.1% aqueous acetic acid–
acetonitrile (90/10, vv
 1), and pumped at a flow rate of
1.0mlmin
 1.
A calibration curve was analysed using acidified plasma samples
freshly spiked in triplicate. Each sample contained 0.10, 0.20, 0.50,
1.0, 5.0, 10.0, and 20.0mgml
 1 of temozolomide per millilitre and a
fixed amount (1.0mgml
 1) of IS. Similarly prepared quality control
samples, which had been spiked with temozolomide (0.2, 1.5, and
15.0mgml
 1) and stored frozen (–801C), were processed and
assayed in triplicate. Standard curves were constructed by plotting
the ratio of temozolomide peak areas to those of the IS vs known
plasma concentrations. A linear response between 0.10 and
20.0mgml
 1 was observed (r40.99) for all calibration curves.
The coefficient of variation ranged between 0.0 and 3.7%, the bias
ranged from –10.0 to 7.5%, and the interassay coefficient of
variation (CV%) was no more than 6.9% over analysis period.
Pharmacokinetic and pharmacodynamic analyses
Individual temozolomide plasma concentration data sets from
days 1, 15, and 21 were analysed by noncompartmental methods.
Peak concentrations were determined from inspection of indivi-
dual patient plasma concentration–time curves. Elimination rate
constants were estimated by linear regression of the last three data
points on the terminal log linear portion of the concentration–
time curves. Terminal half-lives (t1/2) were calculated by dividing
0.693 by the elimination rate constants. Values for area under the
concentration vs time curve (AUC) were calculated using the linear
trapezoidal rule up to the last measurable data point (AUC0 t),
or extrapolated to infinity (AUC0 N). The apparent systemic
clearance (CL/f) was determined by dividing the dose of temoz-
olomide in mgm
 2) by the AUC. The temozolomide AUC up to the
time of PBMC sampling for AGAT activity (AUC0 t) was estimated
by multiplying the AUC0 N on day 1 and the number of days of
continuous temozolomide administration prior to PBMC sam-
pling.
The relations between the percentage AGAT inactivation
percentage and pharmacokinetic parameters reflecting exposure
were explored. Specific pharmacokinetic parameters that were
evaluated included AUC0 N values on day 1 and total AUC up to
the time of PBMC sampling (AUC0 t), estimated as the product of
AUC0 N and the number of days of treatment up to PBMC
sampling days and Cmax days) and the percent decrement in
AGAT activity from pretreatment values in course 1 were explored.
The percentage inactivation of AGAT activity was calculated as
follows: 100%  [pretreatment AGAT activity AGAT activity at
sampling]/pretreatment AGAT activity]). Pharmacodynamic rela-
tions were fit to a linear model and a maximal effect (Emax) model
of drug action, in which the percentage change in
AGAT¼Emax AUCg0/AUC50g+AUCg). The maximal effect (Emax)
was fixed at 100%, the AUC50g was the AUC at which the effect is
50% of the maximal effect, and the exponent g was a constant that
describes the sigmoidicity of the curve. Both simple and sigmoidal
Emax models were fit to the data by nonlinear least-squares
regression. The coefficient of determination (R
2) and the standard
errors for the estimated parameters were used as measures of
goodness of fit for the pharmacodynamics model. Parameter
values were expressed as means and standard deviation values.
The relations between the percent decrement in platelets and
neutrophils from baseline over the first two courses and the
percent decrement of AGAT activity in the first course were
explored. The percent decrements in blood cell counts were
calculated as follows: 100% ([pretreatment counts nadir
counts]/pretreatment counts). The relations between decrements
in platelet and neutrophil counts and AGAT were assessed both by
a linear model of correlation, and by using an Emax model.
Statistical analysis
Mean values for AGAT activity were calculated and compared
using either a paired or unpaired Student’s t-test. Analysis of
variance (repeated measures) was used to compare the mean
AGAT activity of patients sampled at pretreatment, days 15 and 22.
The correlation coefficient (Spearman) was calculated for decre-
ments in AGAT activity and decrements in neutrophil and platelet
counts.
RESULTS
General
A total of 72 patients were entered onto the two concurrent phase I
studies of temozolomide administered on Schedules A and B. For
Schedule A, the maximum tolerated dose (MTD) of temozolomide
was determined to be 150mgm
 2day
 1 for 7 days every 2 weeks
for both minimally and heavily pretreated patients (Figueroa et al,
2000). For Schedule B, the MTDs were determined to be 85 and
100mgm
 2day
 1 for 21 days every 4 weeks for heavily and
minimally pretreated patients, respectively (Denis et al, 2000).
Severe thrombocytopenia, often associated with severe neutro-
penia, was the principal dose-limiting toxicity encountered with
both administration schedules. The complete clinical toxicologic and
pharmacokinetic profiles of temozolomide on these schedules are
being reported separately (Denis et al, 2000; Figueroa et al, 2000).
Effects of temozolomide on PBMC AGAT activity
Peripheral blood mononuclear cells were collected serially in 52 of
the 72 patients enrolled in the two clinical studies. In all, 20
patients did not have samples collected; 10 who were entered into
the clinical studies prior to the protocol amendment for AGAT
analysis, and 10 patients who had inadequate samples for analysis.
O
6-alkylguanine-DNA alkyltransferase activity in PBMCs was
measured serially in 25 and 27 patients treated with temozolomide
on Schedules A and B, respectively. Scatterplots of all assessments
of PBMC AGAT activity are displayed in Figure 1A, B. In patients
treated with temozolomide on Schedule A, marked inactivation of
AGAT was noted after 7 days of daily treatment, at which time
AGAT activity decreased by 72%, on average, from 6.9574.7 to
1.9572.11fmolmg
 1 DNA (paired t-test, Po0.0001). Similarly,
mean AGAT activity decreased by 63 and 73% from pretreatment
levels following 14 and 21 days of temozolomide treatment
(Schedule B), respectively (paired t-test, Po0.001 for both
comparisons). In the subsets of patients treated at the MTDs,
mean AGAT activity decreased by 80.1714.1% after 7 days of
temozolomide treatment (Schedule A), whereas mean AGAT
activity decreased by 74.5716.4% after 21 days of treatment
(Schedule B) (paired t-test, Po0.0001 for both comparisons).
After 7 days of daily temozolomide treatment, the percentage
decrements in AGAT activity were generally greater at the higher
dose levels (125, 150, and 175mgm
 2day
 1) than at the lower dose
levels (75 and 100mgm
 2day
 1), although the small number of
patients treated at the lowest dose level were insufficient to provide
statistical analysis of the dose-dependence of AGAT inactivation.
The percentage decrements in AGAT activity averaged 5170,
4875, 81713, 80714, and 76716% following 7 days of treatment
AGAT inactivation with protracted temozolomide schedules
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lwith temozolomide doses of 75, 100, 125, 150, and
175mgm
 2day
 1, respectively. With more protracted temozolo-
mide treatment (14 and 21 days), dose-related effects were no
longer apparent and AGAT inactivation was similar at all dose
levels. Furthermore, AGAT inactivation following 14 and 21 days
of treatment with low doses temozolomide (85 and
100mgm
 2day
 1) was comparable to that achieved with higher
doses (125, 150, and 175mgm
 2day
 1) administered for 7 days
(Figure 2A–E).
Since both dose and duration of temozolomide treatment
appeared to be related to AGAT inactivation, relations between
AGAT inactivation and both total temozolomide dose and AUC0 t
were sought. A scatterplot of the percentage decrements in AGAT
activity in all PBMC samples as a function of the total
temozolomide dose (in mg) and plasma AUC administered up to
the time of PBMC sampling is displayed in Figure 3. Although
neither linear nor nonlinear models were adequate in relating
temozolomide and Cmax, or AUC0 t, values on day 1 to changes in
AGAT activity, a simple Emax model marginally described the
relations between decrement in AGAT activity and total temozo-
lomide dose (R
2¼0.104), as shown in Figure 3A, while the relation
between the percentage decrement in AGAT activity following 7–
21 days of treatment and total drug exposure estimated up to the
time of PBMC sampling (AUC0 t days) was more appropriately
described by a sigmoidal Emax model (R
2¼0.1881), as shown in
Figure 3B.
Recovery of PBMC AGAT activity
The recovery of AGAT activity following treatment was studied
thoroughly in patients treated with temozolomide on Schedule A.
Marked and significant reductions in AGAT activity from
pretreatment levels persisted on day 15 (Figure 4), which was
7 days after the first series of seven daily treatments and
immediately before the next 7-day course (Po0.001, paired
t-test). After the 7-day treatment-free period, mean AGAT activity
recovered to only 55% of the initial level prior to treatment.
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6-alkylguanine-DNA alkyltransferase inactivation and
toxicity
Relations between AGAT inactivation and the principal toxicities
of temozolomide on both Schedules A and B were sought. Neither
linear nor nonlinear models adequately described the relations
between the percentage changes in platelet and neutrophil counts
and AGAT inactivation. However, the percentage decrements in
AGAT activity were significantly greater in Schedule B patients
who experienced grade 3 or 4 thrombocytopenia compared to
those who did not experience severe platelet toxicity (mean
percentage AGAT inactivation, 90.375.5 vs 72.5716.1%,
Po0.045). Both groups of patients received treatment with similar
total temozolomide doses (mean total temozolomide doses,
45157556 vs 408371079mg (P¼0.44)). The low number of
severe thrombocytopenic events in patients treated with temozo-
lomide on Schedule A may have limited the statistical power of
similar analyses in these patients.
DISCUSSION
The results of both experimental and clinical studies have
indicated that AGAT activity is an important determinant of
tumour sensitivity to several types of DNA-damaging agents, such
as methylating and chloroethylating agents, which target the O
6
position of guanine (Dumenco et al, 1989; Schold et al, 1989; Pegg,
1990; Esteller et al, 2000). Therefore, strategies directed at
inactivating AGAT, particularly those resulting in preferential
AGAT inactivation in malignant tissue, may enhance the
antitumour activity, and possibly the therapeutic indices of
relevant anticancer agents. The current study was performed to
characterise the magnitude and temporal aspects of AGAT
inactivation in PBMCs in the course of developing protracted
schedules of the oral, DNA methylating agent temozolomide,
which has undergone regulatory approval for treating patients with
anaplastic astrocytoma on a daily 5-day every 4-week schedule,
and has also demonstrated prominent activity against other central
nervous system malignancies and melanoma. The rationale for the
present studies is the high rate of anticancer activity noted
following treatment of patients with malignant brain tumours with
more protracted, low-dose temozolomide schedules (Newlands
et al, 1992; Brock et al, 1998), as well as the hypothesis that the
administration of DNA methylating and chlorethylating agents on
protracted schedules may progressively lead to greater inactivation
of AGAT and inhibition of recovery of AGAT activity to a much
greater extent than less protracted schedules. In essence, admin-
istration schedules that lead to the progressive inactivation of
AGAT may ‘auto-enhance’ the innate cytotoxicity of DNA-
damaging agents.
The results of the current study support the assertion of Brock
et al (1998) that cumulative ‘schedule-dependent’ inactivation of
AGAT is, in part, responsible for the level of activity noted in
preliminary studies of temozolomide administered on protracted
schedules. In the present study, profound and persistent AGAT
inactivation was noted with two low-dose protracted schedules of
temozolomide. The total dose of temozolomide, duration of
treatment and temozolomide exposure (AUC0 t number of days)
however were only approximate determinants of AGAT inactiva-
tion. Instead, substantial, albeit nearly equivalent, degrees of
AGAT inactivation were observed with many iterations of
temozolomide doses and protracted treatment periods. These
results suggest that there may be thresholds with regard to
temozolomide dose levels, treatment periods, and pharmacologic
exposure, above which further AGAT inactivation does not occur
and with low dose administered for prolonged schedules this
threshold is exceeded with temozolomide. For example, although
the magnitude of AGAT inactivation appeared to be greater at the
highest dose levels following 7 days of treatment, dose-dependent
differences in AGAT inactivation were not apparent following 14
and 21 days of treatment. In fact, the MTD for Schedule B,
85mgm
 2day
 1, resulted in nearly equivalent AGAT inactivation
following 14 and 21 days of temozolomide as 7 days of treatment
with higher doses (125–175mgm
 2day
 1). However, these results
do not necessarily imply that the antitumour activity of low doses
of temozolomide administered for more protracted periods will be
equivalent to that resulting from higher doses administered for less
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Figure 3 (A) Scatterplot of the percentage values of PBMC AGAT
inactivation as a function of the total cumulative temozolomide dose
administered up to the time of PBMC sampling (R
2¼0.102). (B)
Scatterplot of temozolomide exposure as the product of AUC0-t multiplied
by total days temozolomide administered prior to PBMC sampling
(R
2¼0.188).
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Figure 4 Mean (s.d.) AGAT activity at baseline and day 8, and recovery
at day 15 following administration of temozolomide on days 1–8.
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many, as of yet unknown, determinants of temozolomide activity.
Other investigators have described the absence of a strong
relations between temozolomide dose and AUC and AGAT
inactivation. Similar to the current study, Gander et al (1999)
found that no relation was apparent between AGAT inactivation
and temozolomide AUC when temozolomide was administered in
divided doses over 2 days.
As expected, myelosuppression, particularly severe thrombo-
cytopenia, was the principal dose-limiting toxicity of temozolo-
mide in patients treated with the agent on both Schedules A and B.
For patients treated on Schedule B, AGAT inactivation in PBMC
was significantly greater in patients who experienced severe
thrombocytopenia than in those who did not. This relation was
apparent despite the heterogeneity of the patient population with
regard to the extent of prior therapy, which had previously been
demonstrated to be a strong determinant of severe thrombocyto-
penia on protracted temozolomide schedules (Denis et al, 2000;
Figueroa et al, 2000). Based on the nature of the clinical toxicities
observed, as well as experimental evidence indicating that
haematopoietic progenitors, particularly megakaryocyte precur-
sors, have inherently low AGAT activity, it may be speculated that
these progenitor cells are especially sensitive to strategies that
inactivate AGAT (Gerson et al, 1996).
Several therapeutic approaches designed to inactive AGAT using
methylating agents have been evaluated. One approach to achieve
maximal inactivation of AGAT is to administer sequentially DNA-
damaging agents; however, initial evaluations using streptozotocin
have provided little enthusiasm for broader investigations of this
strategy (Willson et al, 1995; Smith et al, 1996). For example,
Willson et al (1995) evaluated a sequential regimen of streptozo-
tocin, which was administered to inactivate AGAT, followed by
treatment with BCNU. Although this particular approach was
supported by preclinical data, in which the drug combination
produced superior anticancer activity compared to BCNU alone,
improved antitumour activity was not observed, and pulmonary
toxicity was substantial (Panella et al, 1992; Smith et al, 1996). An
alternate strategy using imidazotetrazinone methylating agents has
been used. Lee et al (1993a, b) examined the use of sequential
DTIC prior to fotemustine. DTIC markedly reduced PBMC AGAT
and this effect occurred rapidly (within 1–6h). The magnitude of
AGAT reduction was greater for doses over 400mgm
 2 compared
to 400mgm
 2, but no dose–response effect was noted between
500 and 800mgm
 2. Similar to the current study, DTIC also led to
prolonged AGAT inactivation. Moreover, Philip et al (1996) noted
inactivation (that persisted for up to 24h in 11 patients and AGAT
remained partially inactivated after 3 weeks in 13 patients. Other
investigators have documented similar reductions of AGAT that
only partially recovered 3 weeks from dosing (Middleton et al,
2000). These findings are in agreement with the current study, in
which AGAT remained partially inactivated after 7 days without
temozolomide treatment, and indicate a similarity in time course
and persistence of AGAT depletion across the class of imidazote-
trazinone methylating agents (Lee et al, 1994).
O
6-alkylguanine-DNA alkyltransferase activity in PBMCs has
been used as a pharmacodynamic surrogate end point in several
clinical studies of DNA-damaging agents, although changes in
AGAT activity in PBMCs may not reflect changes in tumour tissues
with some agents (Willson et al, 1995; Spiro et al, 1999). Spiro et al
(1999) reported that AGAT inactivation in PBMCs occurs at an
earlier time point and is more profound in PBMCs than in
malignant tissues following treatment with O
6BG. The investigators
demonstrated that AGAT activity was undetectable in the PBMCs
of patients within 15min following O
6BG treatment, whereas
AGAT inactivation in tumour samples was first noted at least 18h
after treatment (Spiro et al, 1999). Furthermore, 5- to 12-fold
higher doses of O
6BG were required to inactivate completely
intratumoural AGAT (Spiro et al, 1999). Other investigators have
noted tumour AGAT reductions following temozolomide admin-
istration, but these studies were small and the sampling time for
AGAT inactivation after temozolomide administration was brief
(4h) (Gander et al, 1999). These earlier publications therefore
question the accuracy of PBMCs as a surrogate for tumour AGAT
activity. It should not be presumed, however, that these results are
readily applied to the findings in the current study. The current
study’s temozolomide schedules used protracted and cumulative
exposure to deplete AGAT, and the PBMCs were sampled at later
time points to examine these cumulative effects. In contrast, the
previous clinical studies of O
6BG and temozolomide utilised
schedules that permitted only a relatively brief exposure to O
6BG
and sampling of PBMC and tumour tissue AGAT was performed at
early time points. The differences between decrements in PBMC
and tumour tissue AGAT following a relatively brief exposure to
O
6BG and temozolomide may merely reflect the difference between
O
6BG plasma and tissue concentrations. In the current study,
however, temozolomide dose and plasma concentration (Cmax and
AUC(0 t)) appeared to influence AGAT inactivation only with the
short 7-day schedule and not with more prolonged treatment
where maximal inactivation occurred even with low doses and
plasma concentrations. Since studies have not examined AGAT
depletion in PBMC and tumour tissues following protracted O
6BG
or temozolomide schedules, it remains to be determined whether
the aforementioned pharmacodynamic studies of O
6BG and
temozolomide that utilised brief exposure schedules are relevant
to the current study utilising protracted schedules. To better
address this question, an examination of AGAT activity in PBMC
and tumour tissue following prolonged temozolomide exposures
would be an appropriate next step in the clinical development of
these schedules.
Complete inactivation of AGAT may not be necessary to achieve
maximal clinical activity. Instead, there may be specific threshold
levels of AGAT activity, below which maximal cytotoxicity occurs
(Wedge et al, 1997; Kokkinakis et al, 2001). This phenomenon has
been demonstrated in mice bearing human glioblastoma xeno-
grafts, in that progressively decreasing AGAT activity in a tumour
cell line with AGAT activity of 45fmolmg
 1 protein by adminis-
tering O
6BG does not result in any further enhancement of
alkylator antitumour efficacy (Kokkinakis et al, 2001). In addition,
both failure-free survival and overall survival were significantly
longer following BCNU treatment in patients with brain tumours
that expressed low to intermediate levels of AGAT
(o60 000molecules per nucleus) compared to those with tumours
expressing high levels of AGAT (progression-free survival, 6 vs 3
months (P¼0.008); overall survival, 29 vs 8 months (Po0.0002))
(Jaeckle et al, 1998). This relation of AGAT expression and clinical
outcome in brain tumour patients, a tumour site in which
methylating/alkylating agents have some utility, may not be
applicable in other malignancies, where the mechanisms of
chemotherapy resistance may be independent of AGAT expression
(Middleton et al, 1998). In the present study, AGAT activity
decreased by 80 and 75% following 7 and 21 days of treatment with
temozolomide on well-tolerated dose-schedules. However, addi-
tional biochemical and clinical studies designed to define a range
or threshold level of AGAT inactivation, for which to target with
modulating strategies, will undoubtedly facilitate the development
of temozolomide dose-schedules with superior therapeutic indices
in those tumour sites, where methylating agents have utility
(Friedman et al, 1998).
The sustained inactivation of AGAT 7 days after treatment with
temozolomide on the protracted schedules evaluated in the present
study may have important implications for selecting dose-
schedules for further clinical evaluations. Although the magnitude
of AGAT inactivation and the temporal nature of its regeneration
following treatment with temozolomide on its approved schedule,
150–200mgm
 2day
 1 for 5 days every 4 weeks, have not been
studied, it can reasonably be speculated that partial or complete
AGAT inactivation with protracted temozolomide schedules
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interval between each 5-day course of temozolomide. In contrast,
both Schedules A and B in the present study incorporate a much
shorter 7-day interval between periods of drug treatment, and,
therefore, temozolomide is always readministered when AGAT is
in an inactivated state. From both biochemical and pharmaco-
logical perspectives, Schedule A is particularly interesting. At the
recommended dose of temozolomide on Schedule A, 150
mgm
 2day
 1 7 days every 2 weeks, peak plasma temozolomide
concentrations and AUC0 t values would be expected to approach
maximally tolerated values, and AGAT inactivation is rapid,
marked, and sustained. Furthermore, temozolomide dose intensity
on Schedule A is 2.8- to 2.1-fold higher than that achieved with its
approved dose-schedule (2100 vs 750–1000mgm
 2 per 4 weeks).
These potential advantages have provided the impetus to begin
disease-directed clinical evaluations of temozolomide on Schedule
A to determine if superior antitumour activity and/or a broader
antitumour spectrum can be achieved (Spiro et al, 2001).
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